Folia Dermatológica Peruana - Vol. 12  Nº. 2 



1.    Magüiña C, Alvarez H, Terashima A y col. La Dapsona (D.D.S) en el Loxoscelismo cutáneo. Diagnóstico 1987; 20:58-64.

2.        Fromm E, Wittmann J. Derivatives of para?nitrosothiphenol. Berichte Deutsche Cl Gesellshaft 1908; 41:2264-73.

3.    Feldman WH, Hinshaw HC, Moses HE. The Effect of promin (diaminodiphenilsulphone dextrose sulphonate) on experimental tuberculosis - Preliminary report. Proc Staff Meet Mayo Clin 1940; 15:695-9.

4.    Faget GH, Pogge RC, Johansen FA, Dinan JF, Prejean VM, Eccles CG. Promin treatment of leprosy. Publ Health Rep 1943; 58: 1729-41.

5.        Chiodini P. The chemoprophilaxis of malaria. J Antimicrob Chemother 1987,20: 297-302.

6.    Booth S.A., Moody CE, Dahl MV y col. Dapsone suppresses integrin?mediated neutrophil adherence function. J Invest Dermatol 1992, 98:135-40.

7.        Thoung-Nguyen V. Kadunce DP, Hendrix JD y col. Inhibition Of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the     treatment of lgA dermatoses. J Invest Dermatol 1993; 100:349-55.

8. Shepard CC, Ellard GA, Levy L y col. Experimental chemotherapy of leprosy. Bull WHO 1976; 53: 425-33.

9.        Zuidema J, Hilbers-Modderman ES, Merkus FW. Clin Pharmacokinet 1986: 11:4 299-315

10.     Buttle G, Stephenson D, Smith, Dewing T, Foster GE. Treatment of streptococcal infections in mice with 4-4 diaminophenylsulphone. Lancet 1937; 1331-4.

11.    Cochrane R, Ramanujam K, Paul H y col. Two and half years experimental work on sulphone group of drugs. Leprosy Rev 1949; 20: 4-64.

12. Lowe J. Treatment of leprosy with diaminodiphenylsulphone by mouth. Lancet 1950; i: 145?50.

13.     Paniker U, Levine N. Dapsone and Sulfapyridine. Dermatologic Clinics 2001; 19:79?86.

14.    Plotkin J, Buell J, Njoku M y col. Methemoglobinemia associated with dapsone treatment in solid organ transplant recipients: A two-case report and review. Liver Transplant Surg 1997; 3:149-52.

15. Ward K, Mc Carthy M. Dapsone?induced     methemoglobinemia. Ann Pharmacother 1998; 32:549-53.

16.    Stone S, GoodwinR. Dapsone?induced jaundice. Arch Dermatol 1978; 114: 947.

17.    Kumar R, Kumar M, Thappa D. Dapsona syndrome: a five year retrospective analysis. Ind J Leprosy 1998; 70:2 71-6.

18.     Smith W. Hypersensitive reactions to dapsone. Lepr Rev 1986; 57:179-80.

19.     Ahrens E, Meckler R, Callen J Dapsone?induced peripheral neuropathy. Int J Dermatol 1986; 25:314-6.

20. Fine J?D, Katz S, Donahue M y col. Psychiatric reaction to dapsone and sulfapyridine. J Am Acad Dermatol 1983; 9274-5.

21. Hofibrand B. Dapsone and renal papillary necrosis. BMJ 1978; 1: 78.

22. Prussick R, Ali Mama, Rosenthal D, Guyant G. The protective effect of vitamin E on the nemolysis associated with Dapsone treatment with dermatitis herpetiformis. Arch Dermatol 1992; 128210-3.

23.    Maguiña C. Alvarez H. Gotuzzo E, Legua P, Echevarria J, Seas nuevos esquemas terapéuticos en Loxoscelismo cutáneo en el HNCH Folia Dermatológica del Perú 1997; 28(2): 23?30.

24.    Sams H, Hearth S, Long L y col. Nineteen documented cases of Loxosceles reclusa envenomation. J Am Acad Dermatol 2001; 44:603-8.

25.    Medina I, Mills J, Leong G v col. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323:776.

26.    Leoung GS, Mills J, Hopewell VC y col. Dapsonetrimethropim for Pneumocystis carinii penummonia in the acquired immunodeficiency syndrome. Ann Intern Med 1994; 121:174.

27.     Gilbert D. Guide to Antimicrobial Therapy 2001.

28.    Paniker U, Levine N. Dapsone an sulfapyridine. Dermatologic Clinics 2001; 19:1?12.

29.     Cañizares 0. Clinical Tropical Dermatology, 1992, 219.

30.     Rogers R, Muller S. Tt of actinomycetoma with dapsone. Arch Dermatol 1974;109..529-34.

31.     Dogra J, Lal B, Misra S. Dapsone in the treatmemt of cutaneous lesihmaniasii. Int J Dermatol 1986; 25:398-400.